Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.
Arta M Monjazeb, Megan E Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A Merleev, Alina I Marusina, Alexander Borowsky, Amin Mirhadi, Stephen L Shiao, Laurel Beckett, Shuai Chen, David Eastham, Tianhong Li, Logan V Vick, Heather M McGee, Frances Lara, Leslie Garcia, Leigh Anne Morris, Robert J Canter, Jonathan W Riess, Kurt A Schalper, William J Murphy, Karen Kelly
Nat Commun 14(1) 5332
摘要
摘要
Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). One third of patients progress and chemotherapy is rarely used in this population. We questioned if addition of the immune-checkpoint-inhibitor (ICI) atezolizumab to standard-of-care SABR can improve outcomes. We initiated a multi-institutional single-arm phase I study (NCT02599454) enrolling twenty patients with the primary endpoint of maximum tolerated dose (MTD); secondary endpoints of safety and efficacy; and exploratory mechanistic correlatives. Treatment is well tolerated and full dose atezolizumab (1200 mg) is the MTD. Efficacy signals include early responses (after 2 cycles of ICI, before initiation of SABR) in 17% of patients. Biomarkers of functional adaptive immunity, including T cell activation in the tumor and response to ex-vivo stimulation by circulating T cells, are highly predictive of benefit. These results require validation and are being tested in a phase III randomized trial.
KM 提取结果
0 个 Figure · 0 个 KM 面板